What are the Clinical Implications of MDSCs in Cancer?
The presence of high levels of MDSCs in cancer patients is often associated with poor prognosis and resistance to therapy. MDSCs can limit the efficacy of immunotherapies, such as checkpoint inhibitors, by maintaining an immunosuppressive environment. Therefore, targeting MDSCs has emerged as a potential strategy to enhance the effectiveness of cancer treatments. Various therapeutic approaches, including the use of MDSC inhibitors, differentiation agents, and immune-modulating drugs, are being explored to counteract the immunosuppressive effects of MDSCs.
